Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ARVN

Arvinas Inc

Dec 05 • 04:00PM ET

24.74

Dollar change -0.65
Percentage change -2.56	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX IONS EXEL NBIX GILD BMRN REGN ALNY SRPT BIIB

| Held by: VTI IWM VB VXF VBK IWO IBB SCHA VTWO XPH

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.67	Insider Own	13.38%	Shs Outstand	68.70M	Perf Week	-4.77%
Market Cap	1.70B	Forward P/E	-	EPS next Y	-4.71	Insider Trans	-0.01%	Shs Float	59.52M	Perf Month	-8.03%
Income	-308.60M	PEG	-	EPS next Q	-0.96	Inst Own	99.95%	Short Float	14.35%	Perf Quarter	1.39%
Sales	161.10M	P/S	10.55	EPS this Y	52.29%	Inst Trans	1.99%	Short Ratio	14.84	Perf Half Y	-10.69%
Book/sh	8.53	P/B	2.90	EPS next Y	-49.23%	ROA	-27.73%	Short Interest	8.54M	Perf Year	6.78%
Cash/sh	16.32	P/C	1.52	EPS next 5Y	-3.50%	ROE	-59.16%	52W Range	21.17 - 53.08	Perf YTD	-39.89%
Dividend Est.	-	P/FCF	-	EPS past 5Y	23.62%	ROI	-52.60%	52W High	-53.39%	Beta	1.83
Dividend TTM	-	Quick Ratio	3.62	Sales past 5Y	80.30%	Gross Margin	53.69%	52W Low	16.86%	ATR (14)	1.58
Dividend Ex-Date	-	Current Ratio	4.17	EPS Y/Y TTM	15.41%	Oper. Margin	-221.85%	RSI (14)	47.55	Volatility	5.98% 6.84%
Employees	445	Debt/Eq	0.00	Sales Y/Y TTM	0.94%	Profit Margin	-191.56%	Recom	1.25	Target Price	60.33
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	42.32%	Payout	-	Rel Volume	0.85	Prev Close	25.39
Sales Surprise	69.09%	EPS Surprise	19.31%	Sales Q/Q	195.95%	Earnings	Oct 30 BMO	Avg Volume	575.23K	Price	24.74
SMA20	-1.60%	SMA50	-3.76%	SMA200	-18.34%	Trades		Volume	491,819	Change	-2.56%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-24	Initiated	Stephens	Overweight	$55
Feb-28-24	Reiterated	Oppenheimer	Outperform	$95 → $80
Feb-14-24	Downgrade	Citigroup	Buy → Neutral	$36 → $55
Feb-01-24	Initiated	Goldman	Buy	$70
Dec-19-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$25 → $63
Dec-06-23	Upgrade	Jefferies	Hold → Buy	$40
Nov-20-23	Upgrade	Guggenheim	Neutral → Buy
Oct-23-23	Upgrade	Wedbush	Neutral → Outperform	$27 → $24
Jun-26-23	Resumed	Oppenheimer	Outperform	$95
Jan-12-23	Downgrade	Guggenheim	Buy → Neutral
Jan-03-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$83 → $49
Sep-09-22	Initiated	Barclays	Overweight	$90
Jun-21-22	Initiated	Jefferies	Hold	$42
May-09-22	Downgrade	Wedbush	Outperform → Neutral
Apr-28-22	Initiated	Credit Suisse	Outperform	$104
Apr-06-22	Initiated	Morgan Stanley	Equal-Weight	$65
Feb-11-22	Resumed	BMO Capital Markets	Outperform	$125
Feb-10-22	Initiated	Wells Fargo	Overweight	$98
Jan-19-22	Initiated	Goldman	Buy	$157
Dec-07-21	Initiated	Cowen	Outperform

Show Previous Ratings

Dec-04-24 01:19PM	Why Is Arvinas, Inc. (ARVN) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Nov-27-24 07:00AM	Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) +6.13%
Nov-25-24 05:35PM	Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-19-24 09:06AM	Arvinas, Inc. (ARVN): This Small-Cap Stock Is Ready To Explode (Insider Monkey) -6.68%
Nov-04-24 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
03:05AM	Loading…
Oct-31-24 03:05AM	Arvinas Inc (ARVN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Promising ... (GuruFocus.com)
Oct-30-24 08:10AM	Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-29-24 09:10AM	Arvinas Inc (ARVN) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-23-24 08:44AM	Arvinas (ARVN): A Small-Cap Biotech with High Growth Potential (Insider Monkey)
Oct-22-24 04:05PM	Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day (GlobeNewswire)
Oct-21-24 07:00AM	Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024 (GlobeNewswire)
Sep-12-24 01:18AM	Vanguard Group Inc's Strategic Acquisition of Arvinas Inc Shares (GuruFocus.com)
Sep-05-24 12:01AM	Arvinas, Inc. (ARVN): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
07:00AM	Loading…
Aug-29-24 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-30-24 01:53PM	ARVN Stock Earnings: Arvinas Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
08:20AM	Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-22-24 08:30AM	HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200 (GlobeNewswire)
Jul-17-24 03:06PM	Biotech Arvinas Stock Earns 82 RS Rating (Investor's Business Daily)
08:44AM	Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains? (Zacks)
Jul-15-24 08:00AM	Milestone Pharmaceuticals Refreshes Board of Directors (GlobeNewswire)
Jun-27-24 09:31AM	Arvinas, Inc. (ARVN): Why Did Analysts Give This Small-Cap Stock a Strong Buy Rating? (Insider Monkey)
Jun-26-24 04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey) +5.76%
Jun-24-24 04:37PM	Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer (GlobeNewswire)
Jun-21-24 07:00AM	Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2 (GlobeNewswire)
Jun-17-24 07:00AM	Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer (GlobeNewswire)
Jun-03-24 04:30PM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire) -15.84%
May-23-24 05:00PM	Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress (GlobeNewswire)
09:10AM	Loading…
May-16-24 09:10AM	Sector Update: Health Care Stocks Steady Premarket Thursday (MT Newswires)
08:07AM	Correction: Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity (MT Newswires)
07:01AM	Arvinas, Pfizer Breast Cancer Treatment Shows 'Encouraging' Clinical Activity (MT Newswires)
06:00AM	Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE) (GlobeNewswire)
May-09-24 04:42PM	Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress (GlobeNewswire)
May-08-24 08:36AM	Oppenheimer Adjusts Arvinas Price Target to $70 From $80, Maintains Outperform Rating (MT Newswires) -5.71%
May-07-24 01:54PM	ARVN Stock Earnings: Arvinas Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) +6.42%
10:27AM	Arvinas Shares Up After Q1 Net Loss Narrows (MT Newswires)
08:15AM	Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-02-24 10:00AM	Why Earnings Season Could Be Great for Arvinas (ARVN) (Zacks)
07:00AM	Arvinas to Present at Upcoming Investor Conferences (GlobeNewswire)
May-01-24 12:00PM	Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Apr-30-24 10:30AM	As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response (PR Newswire)
Apr-26-24 10:00AM	Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-24-24 04:30PM	Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer (GlobeNewswire)
Apr-11-24 04:19PM	Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily)
12:25PM	Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024 (Associated Press Finance)
09:17AM	Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options (Investor's Business Daily)
08:06AM	Novartis pays $150M for Arvinas' phase 3-ready prostate cancer protein degrader (FierceBiotech.com)
07:40AM	UPDATE 2-Novartis taps Arvinas' cancer drug for up to $1 billion (Reuters)
07:17AM	Novartis licenses Arvinas' cancer drug for up to $1 billion (Reuters)
07:00AM	Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer (GlobeNewswire)
Apr-09-24 08:48AM	Is Arvinas (ARVN) Stock a Solid Choice Right Now? (Zacks)
Mar-18-24 04:40PM	Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire) -5.02%
Mar-04-24 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-28-24 08:30AM	Is a Surprise Coming for Arvinas (ARVN) This Earnings Season? (Zacks)
Feb-27-24 08:30AM	Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-23-24 09:55AM	Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High? (Zacks)
Feb-21-24 12:00PM	What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now? (Zacks) -5.73%
Feb-20-24 04:05PM	Arvinas Announces Chief Financial Officer Transition (GlobeNewswire)
07:00AM	Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease (GlobeNewswire)
Feb-14-24 08:00AM	Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer (GlobeNewswire)
Feb-08-24 08:26AM	Goldman Sachs Predicts at Least 45% Rally for These 2 Strong Buy Stocks Heres Why They Have Solid Upside (TipRanks)
Feb-06-24 09:55AM	Wall Street Analysts Think Arvinas, Inc. (ARVN) Could Surge 26.67%: Read This Before Placing a Bet (Zacks) +5.85%
06:45AM	Arvinas and Pfizer's Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer (GlobeNewswire)
Feb-02-24 02:59AM	Arvinas, Inc. (ARVN) Soars 10.0%: Is Further Upside Left in the Stock? (Zacks)
Feb-01-24 04:30PM	Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference (GlobeNewswire) +10.00%
Jan-17-24 12:00PM	What Makes Arvinas, Inc. (ARVN) a New Strong Buy Stock (Zacks)
Jan-16-24 05:01PM	Arvinas Appoints Jared Freedberg as General Counsel (GlobeNewswire)
Jan-01-24 09:55AM	Arvinas, Inc. (ARVN) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
09:40AM	Is Arvinas (ARVN) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-27-23 05:03AM	TipRanks Perfect 10 List: These 3 Top-Scoring Stocks Are Poised to Perform in 2024 (TipRanks)
Dec-25-23 09:55AM	Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade (Zacks)
Dec-18-23 02:58PM	12 Most Promising Cancer Stocks According to Analysts (Insider Monkey)
Dec-15-23 09:40AM	Has Arvinas (ARVN) Outpaced Other Medical Stocks This Year? (Zacks)
Dec-05-23 10:52PM	Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program (GlobeNewswire) +30.77%
01:33PM	Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE ) and Plans to Expand Vepdegestrant Development Program (GlobeNewswire)
Dec-01-23 09:55AM	Does Arvinas, Inc. (ARVN) Have the Potential to Rally 145.52% as Wall Street Analysts Expect? (Zacks) +7.42%
Nov-28-23 05:05PM	Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-27-23 07:00AM	Arvinas Announces Oversubscribed $350 Million Private Placement (GlobeNewswire) +10.24%
Nov-15-23 09:55AM	Wall Street Analysts Predict a 165.07% Upside in Arvinas, Inc. (ARVN): Here's What You Should Know (Zacks)
Nov-13-23 09:55AM	Arvinas, Inc. (ARVN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks) +10.67%
Nov-07-23 08:02AM	Arvinas Inc (ARVN) Reports Q3 2023 Financial Results and Provides Corporate Update (GuruFocus.com) +5.08%
07:00AM	Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-02-23 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-31-23 07:39AM	Strength Seen in Arvinas, Inc. (ARVN): Can Its 6.3% Jump Turn into More Strength? (Zacks) +6.90%
Oct-22-23 07:00AM	Potential of Arvinas' PROTAC AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC (GlobeNewswire)
Oct-18-23 07:00AM	Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day (GlobeNewswire) -6.56%
Oct-15-23 06:07PM	Arvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023 (GlobeNewswire)
06:05PM	Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023 (GlobeNewswire)
Sep-01-23 07:00AM	Arvinas to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-16-23 10:54AM	Oppenheimer Says These 2 Beaten-Down Stocks Could Double Your Money Heres Why They Could Rebound (TipRanks)
Aug-10-23 07:06AM	Wall Street Analysts Trim Price Targets for These 10 Stocks (Insider Monkey)
06:02AM	Growth Investors: Industry Analysts Just Upgraded Their Arvinas, Inc. (NASDAQ:ARVN) Revenue Forecasts By 13% (Simply Wall St.)
Aug-08-23 09:05AM	Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-31-23 04:30PM	Arvinas and Pfizer Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant, an Investigational PROTAC® ER degrader being developed in ER+/HER2- Breast Cancer (GlobeNewswire) +10.26%
Jul-06-23 09:00AM	Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination (GlobeNewswire) -5.94%

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Loomis David K	Chief Accounting Officer	Nov 07 '24	Sale	27.69	231	6,396	8,040	Nov 12 05:34 PM
Houston John G	President and CEO	Feb 23 '24	Sale	47.05	5,196	244,472	1,036,681	Feb 27 06:35 PM
Cassidy Sean A	Chief Financial Officer	Feb 23 '24	Sale	47.05	1,702	80,079	181,916	Feb 27 06:34 PM
Peck Ronald	Chief Medical Officer	Feb 23 '24	Sale	47.05	1,699	79,938	67,516	Feb 27 06:34 PM
Taylor Ian	Chief Scientific Officer	Feb 23 '24	Sale	47.05	1,701	80,032	147,522	Feb 27 06:33 PM
Taylor Ian	Chief Scientific Officer	Jan 04 '24	Option Exercise	16.00	8,252	132,032	109,973	Jan 08 04:39 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARVN

Arvinas Inc

Upgrade your FINVIZ experience